Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Therapeutic Discovery

ORAI1-Mediated Calcium Influx in Lactation and in Breast Cancer

Damara McAndrew, Desma M. Grice, Amelia A. Peters, Felicity M. Davis, Teneale Stewart, Michelle Rice, Chanel E. Smart, Melissa A. Brown, Paraic A. Kenny, Sarah J. Roberts-Thomson and Gregory R. Monteith
Damara McAndrew
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Desma M. Grice
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amelia A. Peters
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felicity M. Davis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teneale Stewart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Rice
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chanel E. Smart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa A. Brown
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paraic A. Kenny
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah J. Roberts-Thomson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory R. Monteith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-10-0923 Published March 2011
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Orai1, Orai2, Orai3, and Trpc1 mRNA expression in the mouse mammary gland during development. Orai1 (A), Orai2 (B), Orai3 (C), and Trpc1 (D) mRNA levels during the 4 stages of mammary gland development. Ct values were normalized to 18S rRNA. Values are relative to the nulliparous sample. Each dot represents mean values from 1 mouse derived from 2 independent real time RT-PCRs, carried out in triplicate. *P < 0.05 compared with nulliparous gland using a 1-way ANOVA with a Tukey multiple comparison posttest. E, Orai1 mRNA levels in HC11 cells. Data are from 3 wells from 3 independent experiments 2 days and 8 days (differentiated) postplating (fold changes are relative to day 2 and are shown as geometric mean ± 95% confidence interval). P*< 0.05 Mann-Whitney test.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    The characterization of ORAI in breast cell lines. A, the expression of ORAI1, ORAI2, and ORAI3 mRNA in breast cell lines; nonmalignant 184A1 and 184B5 and malignant BT-483, MCF-7, ZR-75–1, MDA-MB-321, and T-47D. Data are fold change, normalized to 18S rRNA, and relative to 184A1. Quantitation was based on 2 independent real time RT-PCRs carried out in triplicate. B, inhibition of ORAI1 in MCF-7 and MDA-MB-231 breast cancer cell lines using siRNA compared with nontargeting siRNA (NT siRNA) and mock transfected cells (Mock). The data are mean ± SEM (N = 6) and are from 2 independent experiments. C and D, the effect of ORAI1 inhibition on store-operated calcium influx in MCF-7 (C) and MDA-MB-231 (D) cells. The left panel depicts results typical of 3 independent experiments in each cell line, where relative [Ca2+]I is represented as response over baseline. Data are from individual wells. The first arrow corresponds to the addition of the calcium chelator BAPTA (500 μmol/L), the second arrow (where relevant) refers to the addition of the SERCA inhibitor CPA (10 μmol/L) to deplete calcium stores, and the third arrow to the addition of extracellular Ca2+ (2 mmol/L) to assess store-operated calcium influx. The right panels represent pooled data for the peak ratio (mean ± SEM; N = 12) consisting of the maximal response over baseline value during the Ca2+ influx transient divided by the maximal value obtained during the CPA-induced Ca2+ transient. This more directly assesses store-operated calcium influx through correction of alterations in the degree of calcium store release. *P < 0.05 compared with NT siRNA using a 1-way ANOVA and a Dunnett's multiple comparison post test. E, ORAI1 levels are higher in the basal breast cancer subtype (P = 0.00063, Student's t- test) Oncomine [Version 3.6, Compendia Bioscience, Ann Arbor, MI; (55)].

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    The effect of ORAI1 inhibition in breast cancer cells. A, ORAI1 was inhibited using ORAI1 specific siRNA, and the effect on cell growth in MDA-MB-231 and MCF-7 cells was measured using an MTS assay and compared with nontargeting siRNA (NT siRNA) and mock transfected cells (Mock). Data are percentage of NT siRNA, mean ± SEM (N = 12) from 3 independent experiments. *P < 0.001 using a 1-way ANOVA with a Bonferroni multiple comparison posttest to compare NT siRNA with ORAI1 siRNA for each cell line. B, ORAI1 was inhibited using the nonspecific calcium channel antagonist 2-APB and cell growth was compared with control using an MTS assay. Data are mean ± SEM (N = 8) from 2 independent experiments. *P < 0.001 compared with control using a 2-tailed unpaired t test. C, remodeling of the calcium influx signal in MDA-MB-231 breast cancer cells in the presence of the PAR-2 receptor activator trypsin and ORAI1 inhibition. Results are typical of 3 independent experiments, where relative [Ca2+]I is represented as response over baseline. Data are from individual wells. The first arrow corresponds to the addition of the calcium chelator BAPTA (500 μmol/L), the second arrow (where relevant) to the addition of the trypsin (100 nmol/L), and the third arrow to the addition of extracellular Ca2+ (2 mmol/L) to assess PAR-2-mediated calcium influx. D, pooled data for the peak ratio (mean ± SEM; N = 10–12), which consists of the maximal response over baseline value during the Ca2+ influx transient divided by the maximal value obtained during the trypsin-induced Ca2+ transient. *P < 0.001 using a 1-way ANOVA with a Bonferroni multiple comparison posttest to compare NT siRNA with ORAI1 siRNA. E, ORAI1 expression was inhibited in MDA-MB-231 cells using ORAI1 siRNA and the effect on the percentage of cells in S phase was assessed. Data are from 3 independent experiments carried out in triplicate (mean ±SEM).

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Stim isoform expression in the mouse mammary gland during development and the effect of Stim2 inhibition on basal calcium levels in mammary epithelial cells. For Stim 1 (A) and Stim 2 (B) values are normalized to 18S rRNA and are relative to the nulliparous sample. Each dot represents mean values from 1 mouse derived from 2 independent real time RT-PCRs, carried out in triplicate. C, Stim2 siRNA reduced basal cytosolic calcium levels compared with the nontargeting control. Data are mean ± SEM from 4 independent experiments carried out in quadruplicate. *P < 0.05 compared with nulliparous gland using a 1-way ANOVA with Tukey posttest (Panel A and B) or using a paired t test (Panel C).

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    STIM1 and STIM2 mRNA levels in nonmalignant breast cell lines and breast cancer cell lines. A, STIM1 and STIM2 are not overexpressed in breast cancer cell lines relative to the 184A1 and 184B5 nonmalignant breast cell lines. Data are fold change normalized to 18S rRNA and relative to the 184A1 cell line and are depicted as means derived from 2 independent real time RT-PCRs carried out in triplicate. B, the ratio of STIM1/STIM2 was calculated using ΔCt values normalized to 18S rRNA, then calculating STIM1 expression relative to that of STIM2 for each cell line.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    STIM1 and STIM2 in breast cancer. A, and B, the relationship between STIM1 and STIM2 expression levels in 5 transcriptional subtypes of breast cancer. The expression levels of STIM1 and STIM2 were median-normalized to around zero. All tumors are shown in A and each subtype is highlighted in red in individual graphs in B. Chi-Squared analysis was used to determine if tumors of a particular subtype have a nonrandom STIM1/STIM2 distribution (if STIM1 and STIM2 are unrelated to a particular subtype, the red dots would be expected to be evenly distributed to each of the 4 quadrants). Basal-like tumors predominantly cluster in the lower right quadrant indicating a STIM1high/STIM2low phenotype (P = 0.00018). STIM1/STIM2 levels were randomly distributed in other breast cancer subtypes (P > 0.05). C, the STIM1high/STIM2low phenotype is associated with reduced survival in breast cancer patients. Using Kaplan–Meier analysis, patient survival was compared between tumors from the lower right quadrant of panel A (STIM1high/STIM2low) and the other 3 quadrants (STIM1low/STIM2low, STIM1high/STIM2high, and STIM1low/STIM2high). Significance was evaluated using the log-rank test. D, the effect of STIM1 and STIM2 inhibition on store-operated calcium influx in MDA-MB-231 cells. Data shown are from 4 individual wells from a representative experiment. The first arrow corresponds to the addition of the calcium chelator BAPTA (500 μmol/L), the second arrow (where relevant) refers to the addition of the SERCA inhibitor CPA (10 μmol/L) to deplete calcium stores, and the third arrow to the addition of extracellular Ca2+ (2 mmol/L) to assess store-operated calcium influx. The inset represents pooled data for the peak ratio (mean ± SEM; N = 12), consisting of the maximal response over baseline value during the Ca2+ influx transient divided by the maximal value obtained during the CPA-induced Ca2+ transient. *P < 0.05 compared with NT siRNA using a 1-way ANOVA and a Dunnett's multiple comparison posttest.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 10 (3)
March 2011
Volume 10, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
ORAI1-Mediated Calcium Influx in Lactation and in Breast Cancer
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
ORAI1-Mediated Calcium Influx in Lactation and in Breast Cancer
Damara McAndrew, Desma M. Grice, Amelia A. Peters, Felicity M. Davis, Teneale Stewart, Michelle Rice, Chanel E. Smart, Melissa A. Brown, Paraic A. Kenny, Sarah J. Roberts-Thomson and Gregory R. Monteith
Mol Cancer Ther March 1 2011 (10) (3) 448-460; DOI: 10.1158/1535-7163.MCT-10-0923

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
ORAI1-Mediated Calcium Influx in Lactation and in Breast Cancer
Damara McAndrew, Desma M. Grice, Amelia A. Peters, Felicity M. Davis, Teneale Stewart, Michelle Rice, Chanel E. Smart, Melissa A. Brown, Paraic A. Kenny, Sarah J. Roberts-Thomson and Gregory R. Monteith
Mol Cancer Ther March 1 2011 (10) (3) 448-460; DOI: 10.1158/1535-7163.MCT-10-0923
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Grant Support
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Sorafenib Targets VCP in Hepatocellular Cancer Cells
  • RSK2 as Therapeutic Target for Myeloma
  • Dll4-Fc Suppresses Liver Metastasis of SCLC Cells
Show more Therapeutic Discovery
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement